Company Update

DXS INTERNATIONAL PLC (AQSE: DXSP)

ExpertCare selected for prestigious Grow Digital Health Midlands Programme

DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme.

Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands, has announced its first cohort of nine high-potential digital health companies of which DXS and the ExpertCare solution is one. The programme is designed to help UK technology innovators scale proven solutions across the NHS and wider care system.

Following a competitive process receiving 51 applications, nine have been successful and will receive a tailored package of support, including:

  • Access to subject matter experts to aid product development; and
  • Significant opportunities to showcase DXS’s innovations to NHS and care system decision-makers and influencers.

Gaining exposure to the largest NHS England region, encompassing 11 Integrated Care Systems and a population of approximately 11.8 million people, Grow Digital Health Midlands provides a platform to bring forward digital innovation that can address the NHS’s most pressing challenges. The key themes for the cohort were to seek innovators who have solutions that enhance NHS productivity and communication and can reduce the demand for hospital based care.

Tim Robinson, Health Innovation East Midlands Commercial Director, said: We’re proud to welcome the nine exciting innovators to our Grow Digital Health Midlands programme.

This programme has been shaped by input from NHS and care leaders across the Midlands and is aligned with the government's national priorities, including the government's three shifts.* It was paramount that the companies demonstrated this as part of their application, demonstrating relevance and technology readiness.

We’re excited to support their innovator journeys, and their growth to bring change to our health and care systems.”

* The 10 Year Health Plan is set to outline three significant shifts that the government wants to make in health and care – from an analogue system to a digital one, from care in hospitals to care in the community, and from a system that treats sickness to one that prevents ill health.

The Directors of DXS International plc accept responsibility for this announcement. This announcement contains information which, prior to its disclosure, was inside information as stipulated under Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

David Immelman

DXS International plc

-systems.com





 
01252 719800
AQSE Corporate Broker and Corporate Advisor

Hybridan LLP

Claire Louise Noyce
020 3764 2341

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively and which should significantly contribute towards the NHS achieving its projected efficiency savings.



EN
10/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DXS International PLC

 PRESS RELEASE

Company Update

Company Update DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare selected for prestigious Grow Digital Health Midlands Programme DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to announce that ExpertCare, its digital medicine solution, has been selected for the prestigious Grow Digital Health Midlands Programme. Grow Digital Health Midlands - a new collaboration from Health Innovation East Midlands and Health Innovation West Midlands, has announced its first cohort of nine high-potential digital health companies of which DXS and the ...

 PRESS RELEASE

Statement re Grant of Options and Warrants

Statement re Grant of Options and Warrants DXS INTERNATIONAL PLC (AQSE: DXSP) Granting of Share Options and Warrants The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, announces that it yesterday granted share options to a number of directors, employees, and consultants. Most of these options grants are under an Enterprise Management Incentive (“EMI”) scheme and the remainder under an unapproved share option scheme. All these Share Options are at an exercise pric...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 13 February, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,333.756 Ordinary Shares representing 2.0...

 PRESS RELEASE

Director/PDMR Shareholding

Director/PDMR Shareholding DXS INTERNATIONAL PLC (AQSE: DXSP) Notification of Director / PDMR Dealing DXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 31 January, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share. Following this transaction Mr Sutcliffe and his wife’s interest in DXS Ordinary Shares is 1,303.756 Ordinary Shares representing 2.04...

Hybridan Team
  • Hybridan Team

Hybridan Monthly, 3 February 2025

2025: The year of the Phoenix, NOT the Unicorn The pursuit of Unicorn companies valued at $1bn+ will always be newsworthy and exciting. VCs, Private Equity, Governments and Global Stock Exchanges will continue to fight and clamber over one another for the chance of courting them. Our collective attention should therefore not be where support is needed least. Our attention needs to be diverted back to the exciting and unloved. The majestic Phoenix company; known for its ability to be reborn f...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch